Good afternoon, everyone, and welcome to our fourth quarter 2025 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Jay Bradner, Murdo Gordon ...
Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the ...
Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after a pair of positive phase 3 trials. The South San Francisco biotech said ...
TL;DR: If you're looking for a powerful productivity suite without recurring subscription fees, Microsoft Office 2021 is available for just $35 for a limited time, an incredible deal. This offer ...
F rom topicals and light therapy to systemic medications, a variety of treatments are available to treat psoriasis. Because each option is unique, some will work better for you than others. A ...
Zacks.com on MSN
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?
We expect Amgen AMGN to beat expectations when it reports fourth-quarter and full-year 2024 results on Feb. 4, after market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results